Informations générales (source: ClinicalTrials.gov)
Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)
Interventional
N/A
Gustave Roussy, Cancer Campus, Grand Paris (Voir sur ClinicalTrials)
mai 2023
mai 2028
02 mars 2026
To engineer immune organoids from pediatric patient tissues using induced-pluripotent
stem cells (iPSC)
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Claudia PASQUALINI | 17/04/2024 09:59:58 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Necker-Enfants Malades | Kevin BECCARIA | Contact (sur clinicalTrials) | |||
| CLCC INSTITUT GUSTAVE ROUSSY | Claudia PASQUALINI | Contact (sur clinicalTrials) | |||
Critères
Tous
- Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal
tumors for whom no upper age limit is applied
- Medical suspicion or diagnosis of one of the following diseases, regardless of
stage:
- Brain tumors
- Renal tumors
- Neuroblastoma
- Sarcomas
- Adult patient or parents or guardians should understand, sign and date the
appropriate written informed consent from prior to any protocol-specific procedures
performed. Patient should be able and willing to comply with study visits and
procedures as per protocol.
- Affiliated to a social security system or beneficiary of the same.
Exclusion Criteria:
- Any histology not mentioned in the inclusion criteria
- Adult patient or parents/guardians incapable/incapable of giving its/their consent
- Patients deprived of their liberty by a judicial or administrative decision